Biomerica IncBMRA
Price (close)
$2.32
Market cap
$10.6M
P/E
—
Revenue (TTM)
$4.5M
Net income
-$3.8M
Dividend yield
—
1-year total return
-17.1%
Net margin
-84.8%
Revenue growth
-16.2%
Debt / equity
—
What Biomerica Inc does.
develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Our diagnostic test kits are used to analyze
blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions.
These tests detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances that
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $7.2M | $18.9M | $5.3M | $5.4M | $5.3M | $4.5M |
| Net income | -$7.4M | -$4.5M | -$7.1M | -$6.0M | -$5.0M | -$3.8M |
| Free cash flow | -$5.4M | -$536,000 | -$5.5M | -$5.4M | — | — |
More on BMRA.
- Biomerica Inc summary
- Biomerica Inc financial statements
- Biomerica Inc key metrics
- Biomerica Inc health scores and style box
- Biomerica Inc earnings
- Biomerica Inc dividends
- Biomerica Inc valuation
- Biomerica Inc ownership and insiders
- Biomerica Inc peers
Figures from Biomerica Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.